EcoDrugPlus

Glutamate Ionotropic Receptor Nmda Type Subunit 3b

Ensembl ID : ENSCHAG00000025468
Gene Symbol: GRIN3B
1 Cross references
224 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 3b

Ensembl ID : ENSCHAG00000020110
Gene Symbol: GRIN3B
1 Cross references
227 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 1

Ensembl ID : ENSCHAG00000018442
Gene Symbol: GRIK1
1 Cross references
246 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 1

Ensembl ID : ENSCHAG00000002550
Gene Symbol: GRIK1
1 Cross references
248 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 2

Ensembl ID : ENSCHAG00000013969
Gene Symbol: GRIK2
1 Cross references
197 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 3

Ensembl ID : ENSCHAG00000018120
Gene Symbol: GRIK3
1 Cross references
257 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 4

Ensembl ID : ENSCHAG00000011273
Gene Symbol: GRIK4
3 Cross references
252 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 5

Ensembl ID : ENSCHAG00000026252
Gene Symbol: GRIK5
1 Cross references
289 Possible Orthologues:

Glutamate Metabotropic Receptor 2

Ensembl ID : ENSCHAG00000009645
Gene Symbol: GRM2
1 Cross references
211 Possible Orthologues:

Glutamate Metabotropic Receptor 4

Ensembl ID : ENSCHAG00000006184
Gene Symbol: GRM4
3 Cross references
200 Possible Orthologues:

Glutamate Metabotropic Receptor 4

Ensembl ID : ENSCHAG00000010062
Gene Symbol: GRM4
1 Cross references
214 Possible Orthologues:

Glutamate Metabotropic Receptor 5

Ensembl ID : ENSCHAG00000021920
Gene Symbol: GRM5
1 Cross references
204 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).